Highlights
ASX: ANP       ANTISENSE THERAPEUTICS LIMITED
Last Price Today's Change   Day's Range   Trading Volume
0.053   0.00 (0.00%)  0.052 - 0.053  178,000

Overview

 
Avg Volume (4 weeks):1,076,566
4 Weeks Range:0.044 - 0.058
4 Weeks Price Volatility (%):
64.29%
52 Weeks Range:0.017 - 0.094
52 Weeks Price Volatility (%):
46.75%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

Antisense Therapeutics Limited (ANP) is an Australia-based pharmaceutical drug discovery and development company. The Company is engaged in the research and development of antisense pharmaceuticals. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly, diabetic retinopathy and diabetic nephropathy. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company's product candidate, ATL1101, is an antisense inhibitor of insulin like growth factor 1 receptor (IGF-Ir). It is developing ATL1101 for the treatment of prostate cancer. It is also developing ATL1102 as an inhaled treatment for asthma.

  Be the first to like this.
 


 

632  576  650  9309 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 LKO 0.0010.00 
 CT1 0.018+0.003 
 LTR 0.092-0.006 
 LBT 0.165+0.005 
 TLS 3.59+0.09 
 TTB 0.027-0.003 
 AVZ 0.052+0.009 
 CML 0.026-0.007 
 SCG 3.93+0.13 
 LNY 0.009-0.001 
Partners & Brokers